Skip to content
HowShorted

BIOCRYST PHARMACEUTICALS INC short interest in 2023

In 2023, BIOCRYST PHARMACEUTICALS INC's disclosed short interest ran from 14.00% of shares outstanding on 13 Jan 2023 to 14.69% on 29 Dec 2023, a change of +0.69 percentage points. The year's high was 23.32% on 13 Oct 2023 and its low 14.00% on 13 Jan 2023, averaging 17.60% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 20.02 days on 13 Oct 2023. Full history: BIOCRYST PHARMACEUTICALS INC.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for BIOCRYST PHARMACEUTICALS INC in 2023

2023 in figures

Start of year
14.00% (13 Jan 2023)
End of year
14.69% (29 Dec 2023)
Change
+0.69 pp
High
23.32% (13 Oct 2023)
Low
14.00% (13 Jan 2023)
Average
17.60%
Highest days to cover
20.02 (13 Oct 2023)
SEC filings marked
9

Every report in 2023

BIOCRYST PHARMACEUTICALS INC short interest in 2023
SettlementShort interestDays to coverFilings since previous
13 Jan 202314.00%6.06results (8-K)
31 Jan 202314.16%12.58
15 Feb 202314.32%13.71
28 Feb 202315.64%6.20results (8-K), 10-K filed
15 Mar 202316.35%9.37
31 Mar 202316.57%13.16
14 Apr 202316.11%12.76
28 Apr 202316.52%9.54
15 May 202317.10%10.81results (8-K), 10-Q filed
31 May 202318.83%13.90
15 Jun 202318.78%18.19
30 Jun 202319.79%10.75
14 Jul 202319.97%18.11
31 Jul 202320.58%16.29
15 Aug 202321.14%12.27results (8-K), 10-Q filed
31 Aug 202321.80%19.59
15 Sep 202322.43%16.53
29 Sep 202322.37%16.79
13 Oct 202323.32%20.02
31 Oct 202314.71%7.49
15 Nov 202314.39%8.31results (8-K), 10-Q filed
30 Nov 202314.34%12.25
15 Dec 202314.54%3.99
29 Dec 202314.69%10.40

See also: BIOCRYST PHARMACEUTICALS INC's full history · most shorted US stocks of 2023 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.